United Therapeutics Corporation and Intermountain Health Announce the First Patient Treated with External Liver Support Using a Bioengineered Liver

Published: 2025-06-24 08:20:59 ET UTHR

Published on 06/24/2025 at 08:20

United Therapeutics Corporation and Intermountain Health announced the world's first patient treated in a clinical study of a bioengineered external liver assist product called miroliverELAP®?. This study is the first human clinical trial of a manufactured organ alternative. The procedure was performed on a patient experiencing liver failure who was not eligible for a liver transplant.

The procedure was performed by the team at Intermountain Medical Center in Murray, Utah, led by Christopher J. Danford, MD, a transplant hepatologist at Intermountain Health. Developed by Miromatrix Medical Inc., a United Therapeutics subsidiary, miroliverELAP is an external liver assist combination product consisting of a single-use MIRO-001 bioengineered liver and an extracorporeal blood circuit. The bioengineered liver is made up of a decellularized porcine liver scaffold to which allogeneic3 human endothelial4 and liver cells have been added.

The phase 1 study is open for enrollment of patients with ALF at eight sites in the United States.